Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study)

Psoriasis

Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study

Br J Dermatol.

Bissonnette R, Luger T, Thaçi D, Toth D, Messina I, You R, Guana A, Fox T, Papavassilis C, Gilloteau I, Mrowietz U

doi: 10.1111/bjd.15706.

Psoriasis

Ixekizumab Sustains High Level of Efficacy and Favorable Safety Profile Over 4 Years in Patients With Moderate Psoriasis: Results From UNCOVER-3 Study

J Eur Acad Dermatol Venereol.

Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C

doi: 10.1111/jdv.15921.

Psoriasis

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomised, controlled trial

J Eur Acad Dermatol Venereol

Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C

doi: 10.1111/jdv.17002

Psoriasis

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study

Br J Dermatol.

Reich K, Sullivan J, Arenberger P, Jazayeri S, Mrowietz U, Augustin M, Elewski B, You R, Regnault P, Frueh JA

doi: 10.1111/bjd.19262.

COMMENTED

Psoriasis

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study

Br J Dermatol.

Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, Peris K, Potenza C, Offidani A, Bartezaghi M, Aloisi E, Costanzo A, SUPREME study group

doi: 10.1111/bjd.18013.

Psoriasis

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (≥6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study

Br J Dermatol.

Philipp S, Menter A, Nikkels AF, Barber K, Landells I, Eichenfield LF, Song M, Randazzo B, Li S, Hsu MC, Zhu Y, DePrimo S, Paller AS

doi: 10.1111/bjd.19018.

Psoriasis

First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis

J Eur Acad Dermatol Venereol

Kaul M, Jarvis P, Rozenberg I, Kolbinger F, Di Padova F, Calonder C, Espie P, Rondeau JM, Cebe R, Huber T, Mussmann R, Aassi M, Sligh TS

doi: 10.1111/jdv.17071

Psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

J Eur Acad Dermatol Venereol.

Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M

doi: 10.1111/jdv.15962.

Psoriasis

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial

Br J Dermatol.

Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C

doi: 10.1111/bjd.19341.

Related content

Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study

Ixekizumab Sustains High Level of Efficacy and Favorable Safety Profile Over 4 Years in Patients With Moderate Psoriasis: Results From UNCOVER-3 Study

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomised, controlled trial

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (≥6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study

First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial